S

Sanofi

Global pharma company; vaccines and R&D

Key Account Manager Business Solutions

Full-TimePosted on 10/20/2026Deadline 11/30/26
$122.3k - $176.6k
Mid, Senior
Bachelor's, Master's, MBA
New Mexico, USA+12 moreMore locations: Washington, USA | North Dakota, USA | Oregon, USA | Wyoming, USA | Montana, USA | Nevada, USA | South Dakota, USA | Arizona, USA | Colorado, USA | Nebraska, USA | Utah, USA | Idaho, USA
Remote
Sales & Account ManagementAccount Management

About the job

Requirements
  • A bachelor's degree is required.
  • Three to five years of sales experience is required.
  • Ability to execute tactical initiatives, provide ongoing feedback, and prioritize multiple projects.
  • Strong business acumen and strategic thinking skills.
  • Self-directed and organized, with execution and planning skills.
  • Ability to adapt and change in a shifting environment.
  • Written and oral communication skills.
  • Valid driver's license, eligibility for insurance coverage, and ability to safely operate a vehicle.
  • In-depth knowledge of business planning, negotiation, relationship building across all organizational levels, time management, and presentation skills.
  • Computer skills, including Microsoft Excel, Microsoft PowerPoint, and data analytics.
  • Consensus selling and business communication skills.
  • Project management, sense of urgency, and networking competencies.
Responsibilities
  • Develop business relationships with assigned customers, both through formal contracts and normal business interactions, to differentiate VaxServe products and services and establish VaxServe as the customer's preferred business partner.
  • Interact with and build business relationships across targeted customer organizations, including executive, clinical, quality assurance, purchasing, sales and marketing, drug information, and business development contacts.
  • Network throughout customer organizations to position VaxServe in the marketplace.
  • Work closely with internal and external customers and coordinate and facilitate pull-through activities to maximize contract gross margin across products.
  • Manage Non-SP contract fulfillment in targeted health systems and support identified PBG contracts.
  • Maintain working relationships with VaxServe field sales and Sanofi Pasteur colleagues.
  • Partner with field sales to support training and development of a managed-care-knowledgeable sales force, including conducting field rides in strategic territories; communicating regularly, verbally and in writing, with assigned regions and divisions; participating in and leading cross-functional teams; and attending regional and divisional meetings and providing updates when applicable.
  • Cooperate, collaborate, and communicate appropriately and legally with Sanofi Pasteur colleagues.
  • Partner with customers to identify unmet business needs whose potential solutions align with corporate strategy.
  • Assess opportunities and create business cases to justify solution development.
  • Forecast sales potential arising from business opportunities.
  • Work with the Director of Account Management and other resources to develop and validate solutions and assist with customer implementation.
  • Maintain clear customer communication throughout solution development and implementation.
  • Develop territory business plans describing how product and segment marketing strategies and tactics will be implemented and what collaboration is needed to achieve account goals.
  • Communicate territory plans to senior management and those involved in execution, and adapt plans and customer-level tactics as needed.
  • Manage and report assigned marketing and business travel and entertainment budgets in accordance with policies and procedures.
  • Assist field sales in prioritizing and scheduling sales time, including customer coverage, call frequency, content, and product mix.
  • Determine the sales potential of assigned customers in collaboration with other partners.
  • Gain access to key people within assigned customers.
  • Determine appropriate coverage of customers by field sales personnel.
  • Identify customers' program needs and how VaxServe can help address them.
  • Bring multifunctional teams together for business strategy discussions, problem-solving, and information sharing.
  • Develop best practices.
Desired Qualifications
  • An advanced degree (MA, MS, or MBA) is preferred.
  • Vaccines sales experience is highly preferred.
  • Broad understanding of health system business, decision-making processes, and market trends, with a proven track record of accessing key decision-makers.
  • Proven ability to translate health system market knowledge into strategic plans with internal stakeholders.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
  • June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
  • Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.

What critics are saying

  • Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
  • Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
  • Dupixent concentration makes 2030s patent loss an existential revenue shock.

What makes Sanofi unique

  • Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
  • October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
  • Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Professional Development Budget
  • Parental Leave

Company News

Associated Press
Oct 19th, 2026
Enable Injections wins first Japan approval for enFuse on-body injector via Sanofi's CirCLIQ

Enable Injections has won its first commercial product approval in Japan. The country's Ministry of Health, Labour and Welfare approved the company's enFuse On-Body Delivery System through Sanofi's CirCLIQ Injector. The device delivers a subcutaneous form of Sarclisa (isatuximab) with the push of a button, for treating multiple myeloma. It is the first anticancer treatment given through an on-body injector in Japan. The approval follows recent clearances in the US and Europe. Japan approved Sarclisa SC in June 2026, backed by the IRAKLIA phase 3 study, which showed the subcutaneous form was non-inferior to intravenous delivery. "We're proud to partner with Sanofi to bring our enFuse technology to patients in Japan," said Michael D. Hooven, chairman and chief executive officer of Enable.

Yahoo Finance
Oct 1st, 2026
Sanofi, Regeneron expand alliance in up to $8B deal for immunology drugs

France's Sanofi and US-based Regeneron Pharmaceuticals will expand their 20-year partnership to jointly develop and market immunology medicines in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront, with potential additional payments of up to $7 billion tied to development, regulatory, and commercial targets. The collaboration will add four next-generation immunology drug candidates invented by Regeneron, with one currently in early-stage trials for eczema. The companies will equally share development costs and future profits from new drugs, whilst their existing profit-sharing agreement for top-selling medicine Dupixent remains unchanged. The deal settles prior litigation between the companies and marks an early move by Sanofi's new chief executive Belen Garijo to strengthen the company's pipeline.

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Vicebio

Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Blueprint Medicines

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes the acquisition of Dynavax

Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...